OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016

TAIPEI, TAIWAN, August 31/ — OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), announced it plans to unblind its flagship OBI-822/821 (formerly OPT‐822/OPT‐821) Phase 2/3 clinical trial (Protocol Number OPT-822-001) by March 2016. This decision is based on the recommendations made at its Expert Meeting, held on Friday, 28 August 2015. “The recruitment of […]

HOMEWhat’s NewNewsOBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2015.Jun.04

Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015

2015.Oct.05

OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan